Sign up to save your podcasts
Or
Share CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
A conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. This episode discusses Milotay, G., Little, M., Watson, R.A. et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med (2025). https://doi.org/10.1038/s41591-025-03647-1.
View all episodes
By Oxford UniversityA conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. This episode discusses Milotay, G., Little, M., Watson, R.A. et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med (2025). https://doi.org/10.1038/s41591-025-03647-1.